Latest Sales Performance News

Neuren Pharmaceuticals reports a robust 11% rise in DAYBUE™ US net sales for Q1 2025, alongside a 17% jump in royalty income, setting the stage for an anticipated European market entry in early 2026.

Super Retail Group reports steady sales growth driven by BCF and rebel brands, while facing increased costs from a new distribution centre and HR system upgrades.

JB Hi-Fi Limited reports robust sales growth across Australia and New Zealand in Q3 FY25, maintaining momentum in a competitive retail environment.

Vmoto Limited reported a 16% decline in total unit sales for 1Q25, offset by a strong cash position and strategic investments in e-mobility solutions and production capacity.

Nuchev Limited has entered an exclusive sales agency agreement with Brauer Natural Medicines and H&S Brand Corporation, expanding its footprint in Australia's natural and complementary medicines sector. The deal covers key brands including Brauer, Skin Physics, and Rapid Loss, with potential for broader ANZ distribution.

Burgundy Diamond Mines reported a challenging Q1-2025 with lower ore mined and revenue, yet continues to progress development at Point Lake and Misery mines while strengthening its financial position.

RooLife Group Ltd (RLG) has inked exclusive decade-long agreements with three Chinese companies to market and distribute branded solar energy systems worldwide, marking a strategic expansion into the renewable energy sector.

Burgundy Diamond Mines reported a pivotal Q1 2025, completing the transition to Point Lake open pit mining while securing US$73 million in diamond sales and advancing mine life extension plans to 2030 and beyond.

Reliance Worldwide Corporation posts a robust 14.8% sales increase and a 31.8% jump in net profit for H1 FY25, driven by the Holman acquisition and solid cost efficiencies.

Forbidden Foods Limited has raised $1 million to boost inventory for its Blue Dinosaur and Oat Milk Goodness brands, following a remarkable 104% jump in quarterly sales.

Mirvac Group reported a solid first half with a $236 million operating profit, driven by a 51% surge in residential lot sales and strong development momentum. The company reaffirmed its full-year earnings guidance, signalling confidence in its growth trajectory.

BTC Health has transformed its decade-long license agreement with Arna Pharma into an indefinite partnership, gaining royalties from Singapore and Malaysia sales and first rights to new pharmaceutical products in Australia and New Zealand.